These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37584309)

  • 21. FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French 'FEIBA dans l'hémophilie A acquise' (FEIBHAC) registry.
    Borg JY; Négrier C; Durieu I; Dolimier E; Masquelier AM; Lévesque H;
    Haemophilia; 2015 May; 21(3):330-337. PubMed ID: 25359571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
    Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
    Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.
    Mahlangu J; Oldenburg J; Callaghan MU; Shima M; Santagostino E; Moore M; Recht M; Garcia C; Yang R; Lehle M; Macharia H; Asikanius E; Levy GG; Kruse-Jarres R
    Haemophilia; 2018 Nov; 24(6):921-929. PubMed ID: 30295389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors.
    Mahlangu JN; Andreeva TA; Macfarlane DE; Walsh C; Key NS
    Haemophilia; 2017 Jan; 23(1):33-41. PubMed ID: 27761964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
    Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
    Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A.
    Shapiro AD; Mahlangu JN; Perry D; Pasi J; Quon DV; Chowdary P; Tsao E; Li S; Innes A; Pierce GF; Allen GA
    Haemophilia; 2017 May; 23(3):392-399. PubMed ID: 28220631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A.
    Bullano M; Cool C; Schultz BG; Durgapal S; Sacks N; Liu Y; Kee R; Batt K
    Expert Rev Pharmacoecon Outcomes Res; 2023 Feb; 23(2):225-230. PubMed ID: 36537696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of the B-domain-deleted TQG202 for on-demand treatment in moderate and severe haemophilia A patients: A multicentre, single-arm trial.
    Sun Z; Xi Y; Liu W; Yang L; Wang X; Jin C; Jia H; Zhang L
    Haemophilia; 2023 Jul; 29(4):997-1004. PubMed ID: 36913439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study.
    Santoro C; Fuh B; Le PQ; Maes P; Berrueco R; Mingot-Castellano EM; von Mackensen S; Solms A; Wang M
    Eur J Haematol; 2020 Aug; 105(2):164-172. PubMed ID: 32259334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII.
    Barrow RT; Lollar P
    J Thromb Haemost; 2006 Oct; 4(10):2223-9. PubMed ID: 16856973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors.
    Négrier C; Oldenburg J; Kenet G; Meeks SL; Bordet JC; Müller J; Le Quellec S; Turecek PL; Tripkovic N; Dargaud Y
    Res Pract Thromb Haemost; 2022 May; 6(4):e12731. PubMed ID: 35765670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical safety surveillance study of the safety and efficacy of long-term home treatment with ReFacto utilizing a computer-aided diary: a Nordic multicentre study.
    Petrini P; Rylander C
    Haemophilia; 2009 Jan; 15(1):175-83. PubMed ID: 18752534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study.
    Zhang XH; Zhu XL; Niu T; Sun J; Liu H; Feng R; Yang LH; Wei Q; Ma QH; Wang QM; Feng FE; Fu HX; Mo XD; Lv M; Huang XJ
    Thromb Res; 2015 May; 135(5):835-40. PubMed ID: 25747536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.